Escalation Strategies for Combination Therapy Phase I Trials

Pharmaceutical Statistics - United Kingdom
doi 10.1002/pst.1497
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Escalation With Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials

PLoS ONE
Multidisciplinary
2014English

Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/Ii Trials

Biometrics
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology ImmunologyBiological SciencesMedicineAgricultural
2009English

The Role of Age on Dose-Limiting Toxicities (DLTs) in Phase I Dose-Escalation Trials.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Designs for Phase I Trials in Ordered Groups

Statistics in Medicine
EpidemiologyStatisticsProbability
2016English

Phase I Cancer Clinical Trials

British Journal of Cancer
Cancer ResearchOncology
2007English

Progression-Free Survival Decreases With Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials

Journal of Cancer
Oncology
2012English

A Dynamic Stopping Rule for Phase I Clinical Trials

Biometrical Letters
2018English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy